Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study
Wayne State University · The Barbara Ann Karmanos Cancer Institute · +9 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
693
total citations
- FWCI
- 85.32
- Percentile
- 100%
- References
- 25
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Alectinib
- Crizotinib
- Medicine
- Lung cancer
- ALK inhibitor
- Ceritinib
- Oncology
- Disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.